Mr. F, a Parkinson’s patient in Lausanne, once struggled to take more than a few steps without his legs feeling leaden or slipping beyond his control—until he became one of the first to test a new AI-powered deep brain stimulation system that adapts to his every move. Developed by researchers at EPFL and Lausanne University Hospital (CHUV), this breakthrough therapy is transforming how we treat one of Parkinson’s most debilitating symptoms: walking impairment. While traditional deep brain stimulation (DBS) has helped over 200,000 people worldwide manage tremors and rigidity since its introduction three decades ago, it has long fallen short when it comes to gait. The problem lies in its static design—continuous electrical pulses delivered at fixed settings, regardless of what the patient is doing. For someone navigating stairs, standing up, or turning a corner, that one-size-fits-all approach simply isn’t enough.
Now, thanks to a collaboration between neuroscientists, engineers, and clinicians at the .NeuroRestore center, DBS is getting a real-time intelligence upgrade. By training artificial intelligence on brain signals from 40 Parkinson’s patients, the team created neural decoders that can identify specific locomotor states—like walking, standing, or climbing—from activity in the subthalamic nucleus. These AI models run on a modified Medtronic DBS device, allowing stimulation to be adjusted within seconds based on what the patient is actually doing. The result? A therapy that responds as fluidly as natural movement should.
"Daily locomotor activity involves a variety of activities, such as standing, walking, running, turning or navigating obstacles, each imposing distinct motor requirements," explains Eduardo Moraud, Medtronic Chair in Neuromodulation at EPFL. "This work shows that we can decode many of these activities from neural biomarkers and adapt stimulation to match their physiological demands, helping patients move more naturally." For patients like Mr. F, that means regaining the ability to walk longer distances, stand up from a chair without assistance, and climb stairs with renewed confidence—all without manual intervention or external controls.
The study, published in Nature Medicine, marks a major leap in adaptive neuromodulation. By building on clinically approved hardware, the team has paved a faster path from lab to clinic. Jocelyne Bloch, head of neurosurgery at CHUV and senior co-author, emphasizes the real-world impact: "Walking problems often respond differently to DBS than tremor or rigidity, something clinicians have recognized for years. Our work shows that stimulation settings can be adjusted automatically to meet a person's needs as they move."
With plans for a follow-up study to assess long-term outcomes and expand access to more patients, this intelligent DBS system could soon become a new standard of care. For the millions living with Parkinson’s worldwide, it’s not just about better movement—it’s about reclaiming independence, one step at a time.